MariMed — Third Quarter 2026 Earnings Summary

MariMed Inc. reported record third-quarter 2026 revenue of $44.2 million, representing a 5.5% sequential increase and an 8.5% year-over-year growth. The company achieved a non-GAAP adjusted EBITDA of $4.7 million, up 18% from the previous quarter, while maintaining a non-GAAP gross margin of 40%. Both wholesale and retail segments contributed to this growth, with wholesale revenue rising 5.2% sequentially and retail transactions increasing 2% sequentially. MariMed ended the quarter with $10.4 million in cash and cash equivalents, marking its strongest cash position in over two years.